GeNeuro SA
GEM
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,689.70 | 37.00 | 0.43% |
| CAC 40 | 7,770.95 | 37.45 | 0.48% |
| DAX 40 | 21,042.00 | 51.69 | 0.25% |
| Dow JONES (US) | 44,025.81 | 537.98 | 1.24% |
| FTSE 100 | 8,548.29 | 27.75 | 0.33% |
| HKSE | 19,987.61 | 118.94 | -0.59% |
| NASDAQ | 19,756.78 | 126.58 | 0.64% |
| Nikkei 225 | 39,595.63 | 567.65 | 1.45% |
| NZX 50 Index | 13,074.20 | 21.30 | 0.16% |
| S&P 500 | 6,049.24 | 52.58 | 0.88% |
| S&P/ASX 200 | 8,438.60 | 36.20 | 0.43% |
| SSE Composite Index | 3,229.77 | 12.85 | -0.40% |